Philip Barter, MD
Director, The Heart Research Institute
Professor of Medicine
University of Sydney
Peter P. Toth, MD, PhD
Director of Preventive Cardiology
Sterling Rock Falls Clinic, Ltd.
Chief of Medicine, CGH Medical Center
University of Illinois School of Medicine
The goal of this educational activity is to expand the ability of health care professionals to successfully manage and treat residual risk in cardiovascular disease (CVD) due to abnormally low or dysfunctional HDL.
It has not been proven that increasing the level of HDL-C in humans will translate into a reduction in CVD risk, but this theory remains under investigation. This interactive newsletter will examine numerous HDL-raising therapies under development. Their place in clinical practice will be determined by the results of ongoing human clinical outcome trials.
. Target Audience
Lipidologists, cardiologists, primary care physicians, pharmacists, nurse practitioners, physician assistants, registered nurses and other clinicians who treat patients with dyslipidemia/residual CVD risk.
Upon completion of this knowledge-based educational activity, the participant should be able to:
Develop HDL-targeted lifestyle and therapeutic approaches to reduce residual cardiovascular risk in patients with dyslipidemia.
Describe emerging therapeutic options for enhancing the atheroprotective effects of HDL.
At the conclusion of this activity, Registered Nurses and Nurse Practitioners should be able to provide appropriate care and counsel for patients and their families. Disclosures
Philip Barter, MD, discloses that he has received research funding from Merck and Pfizer, and served on the advisory boards of AstraZeneca, CSL, Lilly, Merck, Novartis, Pfizer, and Roche.
Peter P. Toth, MD, PhD, discloses that he has served as a consultant for Abbott Laboratories, Inc.; AstraZeneca; Kowa Pharmaceuticals America Inc.; Amgen; Amylin Pharmaceuticals; and Merck and Co., Inc. He has served on the speakers' bureaus of Abbott Laboratories, Inc.; AstraZeneca; Boehringer Ingelheim; Merck & Co., Inc.; Kowa Pharmaceuticals America, Inc.; GlaxoSmithKline; and Amylin Pharmaceuticals.
NLA planners and managers have nothing to disclose.
PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, Jan Schultz, RN, MSN, CCMEP, and Patricia Staples, MSN, NP-C, CCRN, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
MCM Education planners and managers have nothing to disclose.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by NLA prior to accreditation of the activity. NLA planners and reviewers have no relevant financial relationships to disclose.
CME credit provided by the National Lipid Association.
The National Lipid Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The National Lipid Association designates this enduring internet activity for a maximum of 0.5 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCPA accepts AMA PRA Category 1 Credits ™ from organizations accredited by ACCME.
CE credit provided by Postgraduate Institute for Medicine.
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Universal Activity Number – 0809-9999-12-386-H01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for .5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education.
This educational activity for .5 contact hours is provided by Postgraduate Institute for Medicine.
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Criteria for Success
Statements of credit will be awarded based on the participant’s successful completion of the post-test with a score of 80% or better and the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/claimed credit form. If you have questions about claiming CME credit, please contact the NLA at firstname.lastname@example.org. If you have questions about claiming CE credit, please contact Postgraduate Institute for Medicine at www.pimed.com. Please claim credit by December 21, 2013.
For Pharmacists transcript information will be available at www.mycpemonitor.net within 4 weeks.
Estimated Time to Complete Activity: 30 Minutes Commercial Support Statements
This activity is supported by an educational grant from Genentech, USA.
Minimum System Requirements
• Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers
Please turn off all pop-up blockers to ensure access to the educational activity.
Click on the "Start program" icon at the bottom of this page. If you are not already registered as a user of this website, this will bring you to the login/registration page where you will be able to register as a new CMEcorner.com member or check existing registration information. When ready, click on the "Continue to Program" icon at the bottom of the screen.
The next screen will permit you to check for or download the Flash player required to run this program and to begin the program presentation. The activity will take approximately 30 minutes to complete.
After the activity has finished, click on the "Post-test" button.
Instructions for completing and submitting the post-test and evaluation are provided on the post-test screen.
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.